Elevated levels of anti-TSH antibodies are estimated to reach 3% in the patients treated with anti-PD-1 [9]; on the other hand, in described cases of nivolumab-induced Graves’ disease, anti-TSH antibodies were negative (the diagnosis was based on the enlargement of glands, hypervascularity at Doppler and increased and diffuse uptake of I131 in scintigram) [74]. Here, PDCD1 is linked to Graves disease.